CervoMed Inc CRVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
CervoMed to Participate in September Investor Conferences
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Trading Information
- Previous Close Price
- $1.45
- Day Range
- $1.45–1.52
- 52-Week Range
- $1.45–10.00
- Bid/Ask
- $1.49 / $1.50
- Shares Outstanding
- 15.12M
- Market Cap
- $22.53M
- Volume/Avg
- 8,034 / 291,101
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.cervomed.com
Valuation
Metric | CRVO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.85 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CRVO
Financial Strength
Metric | CRVO |
|---|---|
Quick Ratio | 8.22 |
Current Ratio | 8.57 |
Interest Coverage | — |
Quick Ratio
CRVO
Profitability
Metric | CRVO |
|---|---|
Return on Assets (Normalized) | −109.47% |
Return on Equity (Normalized) | −130.55% |
Return on Invested Capital (Normalized) | −134.20% |
Return on Assets
CRVO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|G>WT@n | LOCK|kT$Y< | $138B | |||
| Moderna Inc MRNA | LOCK|w$W%%&X | LOCK|?z | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Yxbm!l | LOCK|rWd$ | $93B | |||
| argenx SE ADR ARGX | LOCK|!pM@N! | LOCK|@w | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|xW#@?rY | LOCK|Bgs | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^Ky!NN# | LOCK|>Gwh | $30B | |||
| Incyte Corp INCY | LOCK|C&^BtS! | LOCK|!!# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|S>g>zm | LOCK|<R? | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|ws@@D$% | LOCK|%R?H | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|sYFlNH | LOCK|ZvT | $15B |
United States